Replimune's IPO

Replimune raised a round of funding on July 20, 2018. Investors include Public.

Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the…

Articles about Replimune's IPO: